국가: 캐나다
언어: 영어
출처: Health Canada
RANITIDINE (RANITIDINE HYDROCHLORIDE)
SANOFI CONSUMER HEALTH INC
A02BA02
RANITIDINE
75MG
TABLET
RANITIDINE (RANITIDINE HYDROCHLORIDE) 75MG
ORAL
2/4/10/30/60/124
OTC
HISTAMINE H2-ANTAGONISTS
Active ingredient group (AIG) number: 0115150003; AHFS:
CANCELLED POST MARKET
2022-02-18
_ _ _ZANTAC_ _®_ _ and ZANTAC_ _®_ _ Maximum Strength Non-Prescription Tablets _ _Page 1 of 35_ PRODUCT MONOGRAPH ZANTAC ® Ranitidine Tablets USP 75 mg (as ranitidine hydrochloride) ZANTAC ® MAXIMUM STRENGTH NON-PRESCRIPTION Ranitidine Tablets USP 150 mg (as ranitidine hydrochloride) Histamine H 2 -receptor antagonist Sanofi Consumer Health Inc. 2905 Place Louis-R. Renaud Laval, QC, Canada H7V 0A3 Date of Revision: December 5, 2019 Submission Control No: 231962 _ _ _ZANTAC_ _®_ _ and ZANTAC_ _®_ _ Maximum Strength Non-Prescription Tablets _ _Page 2 of 35 _ TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION ..........................................................3 SUMMARY PRODUCT INFORMATION ........................................................................3 INDICATIONS AND CLINICAL USE ..............................................................................3 CONTRAINDICATIONS ...................................................................................................3 WARNINGS AND PRECAUTIONS ..................................................................................4 ADVERSE REACTIONS ....................................................................................................5 DRUG INTERACTIONS ....................................................................................................7 DOSAGE AND ADMINISTRATION ..............................................................................10 OVERDOSAGE ................................................................................................................10 ACTION AND CLINICAL PHARMACOLOGY ............................................................12 STORAGE AND STABILITY ..........................................................................................16 DOSAGE FORMS, COMPOSITION AND PACKAGING .............................................17 PART II: SCIENTIFIC INFORMATION ...............................................................................18 PHARMACEUTICAL INFORMATION ......... 전체 문서 읽기